Back to top
Top
DERep Home Page

["Patient Characteristic, Race": "Race"]

Performance/Reporting Period
2023
Value Set Description from VSAC
Clinical Focus: n/a Data Element Scope: n/a Inclusion Criteria: n/a Exclusion Criteria: n/a

Constrained to codes in the Patient Characteristic, Race: Race value set (2.16.840.1.114222.4.11.836)

QDM Datatype and Definition

"Patient Characteristic, Race"

Data elements that meet criteria using this datatype should document the patient’s race.

Timing: Race does not have a specific timing. Measures using "Patient Characteristic, Race" should address the most recent entry in the clinical record.

eCQMs using this data element:
CMS104v11 - Discharged on Antithrombotic Therapy
CMS105v11 - Discharged on Statin Medication
CMS108v11 - Venous Thromboembolism Prophylaxis
CMS111v11 - Median Admit Decision Time to ED Departure Time for Admitted Patients
CMS117v11 - Childhood Immunization Status
CMS122v11 - Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)
CMS124v11 - Cervical Cancer Screening
CMS125v11 - Breast Cancer Screening
CMS127v11 - Pneumococcal Vaccination Status for Older Adults
CMS128v11 - Anti-depressant Medication Management
CMS129v12 - Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
CMS130v11 - Colorectal Cancer Screening
CMS131v11 - Diabetes: Eye Exam
CMS133v11 - Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery
CMS135v11 - Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
CMS136v12 - Follow-Up Care for Children Prescribed ADHD Medication (ADD)
CMS137v11 - Initiation and Engagement of Substance Use Disorder Treatment
CMS138v11 - Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
CMS139v11 - Falls: Screening for Future Fall Risk
CMS142v11 - Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
CMS143v11 - Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
CMS144v11 - Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
CMS145v11 - Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF less than or equal to 40%)
CMS146v11 - Appropriate Testing for Pharyngitis
CMS147v12 - Preventive Care and Screening: Influenza Immunization
CMS149v11 - Dementia: Cognitive Assessment
CMS153v11 - Chlamydia Screening in Women
CMS154v11 - Appropriate Treatment for Upper Respiratory Infection (URI)
CMS155v11 - Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents
CMS156v11 - Use of High-Risk Medications in Older Adults
CMS157v11 - Oncology: Medical and Radiation - Pain Intensity Quantified
CMS159v11 - Depression Remission at Twelve Months
CMS161v11 - Adult Major Depressive Disorder (MDD): Suicide Risk Assessment
CMS165v11 - Controlling High Blood Pressure
CMS177v11 - Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment
CMS190v11 - Intensive Care Unit Venous Thromboembolism Prophylaxis
CMS22v11 - Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
CMS249v5 - Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture
CMS2v12 - Preventive Care and Screening: Screening for Depression and Follow-Up Plan
CMS347v6 - Statin Therapy for the Prevention and Treatment of Cardiovascular Disease
CMS349v5 - HIV Screening
CMS506v5 - Safe Use of Opioids - Concurrent Prescribing
CMS50v11 - Closing the Referral Loop: Receipt of Specialist Report
CMS529v3 - Core Clinical Data Elements for the Hybrid Hospital-Wide Readmission (HWR) Measure with Claims and Electronic Health Record Data
CMS56v11 - Functional Status Assessment for Total Hip Replacement
CMS645v6 - Bone density evaluation for patients with prostate cancer and receiving androgen deprivation therapy
CMS646v3 - Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancer
CMS68v12 - Documentation of Current Medications in the Medical Record
CMS69v11 - Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
CMS71v12 - Anticoagulation Therapy for Atrial Fibrillation/Flutter
CMS72v11 - Antithrombotic Therapy By End of Hospital Day 2
CMS74v12 - Primary Caries Prevention Intervention as Offered by Dentists
CMS75v11 - Children Who Have Dental Decay or Cavities
CMS771v4 - Urinary Symptom Score Change 6-12 Months After Diagnosis of Benign Prostatic Hyperplasia
CMS816v2 - Hospital Harm - Severe Hypoglycemia
CMS844v3 - Core Clinical Data Elements for the Hybrid Hospital-Wide (All-Condition, All-Procedure) Risk-Standardized Mortality Measure (HWM)
CMS871v2 - Hospital Harm - Severe Hyperglycemia
CMS90v12 - Functional Status Assessments for Heart Failure
CMS951v1 - Kidney Health Evaluation
CMS996v3 - Appropriate Treatment for ST-Segment Elevation Myocardial Infarction (STEMI) Patients in the Emergency Department (ED)
CMS9v11 - Exclusive Breast Milk Feeding
Last Updated: Jul 15, 2022